Occlutech Obtains CE Mark for its 'Figulla N' ASD and PFO Occluders

Occlutech Obtains CE Mark for its 'Figulla N' ASD and PFO Occluders

October 17, 2007

    JENA, Germany, Oct. 17 /Xinhua-PRNewswire/ -- Occlutech
GmbH, the leading European developer and manufacturer of
cardiac occlusion devices such as ASD, PFO and LAA
occluders today announced that it has received CE mark
approval for its range of ASD and PFO occluder under the
Occlutech Figulla N brand.

    The Occlutech ASD and PFO occluders are uniquely
designed and individually braided, improving performance
over existing technology. The fact that the occluders are
not clamped gives them distinct advantages such as
increased flexibility and a reduction of the amount of
material implanted.

    Occlutech's technology is protected by several patents
and patents pending.

    Starting in Germany, the products will be rolled out in
Europe and in International markets over the next few
months.

    Occlusion devices are used to treat structural heart
disease, including structural heart defects and
abnormalities, such as Atrial Septal Defects (ASD), or
Patent Foramen Ovale (PFO), in a minimally invasive,
non-surgical way. The market for these devices, and the PFO
occluders in particular, are expected to expand
significantly over the next few years.


    For further information please contact:

     Robert Moszner 
     Tel:   [phone] 
     Email: [e-mail] 

     Susanne Goransson
     Tel:   [phone]
     Email: [e-mail]